Akers Biosciences (NASDAQ:AKER) Sees Strong Trading Volume

Shares of Akers Biosciences Inc (NASDAQ:AKER) saw unusually-high trading volume on Tuesday . Approximately 1,997,159 shares were traded during mid-day trading, an increase of 597% from the previous session’s volume of 286,534 shares.The stock last traded at $0.55 and had previously closed at $0.47.

The firm’s 50-day moving average is $0.44.

Akers Biosciences (NASDAQ:AKER) last issued its earnings results on Monday, May 20th. The medical instruments supplier reported ($0.07) EPS for the quarter. The firm had revenue of $0.61 million during the quarter. Akers Biosciences had a negative net margin of 501.62% and a negative return on equity of 135.24%.



An institutional investor recently bought a new position in Akers Biosciences stock. Bank of New York Mellon Corp bought a new stake in Akers Biosciences Inc (NASDAQ:AKER) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 34,274 shares of the medical instruments supplier’s stock, valued at approximately $39,000. Bank of New York Mellon Corp owned approximately 0.27% of Akers Biosciences at the end of the most recent quarter. Institutional investors own 8.42% of the company’s stock.

Akers Biosciences Company Profile (NASDAQ:AKER)

Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.

Read More: What is Cost of Debt?

Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.